Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

20 June 2022: Clinical Research

A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma

Linhua Yao 1ABCEF , Chengwu Tang 2ABCEF , Wenming Feng 2ABFG , Hanbin Dai 2ABCE*

DOI: 10.12659/MSM.937136

Med Sci Monit 2022; 28:e937136

Figure 1 Comparison of relapse-free survival. Relapse was confirmed in 23 patients of the mFFX group and 26 patients of the S-1 group within 3 years postoperatively. The mFFX group demonstrated a markedly higher 3-year relapse-free survival (P=0.0332) and lower hazard ratio for relapse (0.5577, 95% CI, 0.3138 to 0.9910) than the S-1 group. MedCalc software (version 15.2.2, MedCalc Software, Ltd.) was used to create the figure.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750